Nanooncology in ovarian cancer treatment

In the following review, the authors present various methods of using nanoparticles in the therapy of ovarian cancer. Nanoparticles have been shown to prolong the half-time of various chemotheurapeutics, have a lower toxicity, and increase chemosensitivity. It is their hope that this article will widen the discussion within the scientific community on the use of nanotheurapeutics in oncology.

Nanoparticles; Ovarian cancer; Chemotherapy; Nanotherapeutics; Oncology.

[1] Siegel R., Ma J., Zou Z., Jemal A.: “Cancer statistics, 2014”. CA Cancer J. Clin., 2014, 64, 9.

[2] Yallapu M.M., Jaggi M., Chauhan S.C.: “Scope of nanotechnology in ovarian cancer therapeutics”. J. Ovarian Res., 2010, 3, 19.

[3] Engelberth S.A., Hempel N., Bergkvist M.: “Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics”. Crit. Rev. Oncog., 2014, 19, 281.

[4] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol., 2008, 26, 890.

[5] Xiong X., Arvizo R.R., Saha S., Robertson D.J., McMeekin S., Bhattacharya R., Mukherjee P.: “Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles”. Oncotarget, 2014, 5, 6453.

[6] Yang X., Iyer A.K., Singh A., Milane L., Choy E., Hornicek F.J., et al.: “Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer”. Pharm. Res., 2015, 32, 2097.

[7] Yang X., Iyer A.K., Singh A., Choy E., Hornicek F.J., Amiji M.M., Duan Z.: “MDR1 siRNA loaded hyaluronic acidbased CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer”. Sci. Rep., 2015, 5, 8509.

[8] Salzano G., Navarro G., Trivedi M.S., De Rosa G., Torchilin V.P.: “Multifunctional polymeric micelles coloaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer”. Mol. Cancer Ther., 2015, 14, 1075.

[9] Cirstoiu-Hapca A., Buchegger F., Lange N., Bossy L., Gurny R., Delie F.: “Benefit of anti-HER2-coated paclitaxel-loaded immunonanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice”. J. Control Release, 2010, 144, 324.

[10] Guduru R., Liang P., Runowicz C., Nair M., Atluri V., Khizroev S.: “Magneto-electric nanoparticles to enable field-controlled high-specificity drug delivery to eradicate ovarian cancer cells”. Sci. Rep., 2013, 3, 2953.

[11] Huang X., Yi C., Fan Y., Zhang Y., Zhao L., Liang Z., Pan J.: “Magnetic Fe3O4 nanoparticles grafted with single-chain antibody (scFv) and docetaxel loaded β-cyclodextrin potential for ovarian cancer dual-targeting therapy”. Mater. Sci. Eng. C. Mater. Biol. Appl., 2014, 42, 325.

[12] Pašukonienė V., Mlynska A., Steponkienė S., Poderys V., Matulionytė M., Karabanovas V., et al.: “Accumulation and biological effects of cobalt ferrite nanoparticles in human pancreatic and ovarian cancer cells”. Medicina (Kaunas), 2014, 50, 237.

[13] Schumann C., Taratula O., Khalimonchuk O., Palmer A.L., Cronk L.M., Jones C.V., et al.: “ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression”. Nanomedicine, 2015, 11, 1961.

[14] Fleischer A.C., Lyshchik A., Jones H.W. Jr., Crispens M., Loveless M., Andreotti R.F., et al.: “Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings”. J. Ultrasound Med., 2008, 27, 1011.

[15] Fleischer A.C., Lyshchik A., Andreotti R.F., Hwang M., Jones H.W., Fishman D.A.: “Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles”. Am. J. Roentgenol., 2010, 194, 343.

[16] Zhou Z., Wang L., Chi X., Bao J., Yang L., Zhao W., Chen Z, et al.: “Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging”. ACS Nano., 2013, 7, 3287.